Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum
Fresenius Medical Care (FMS) has released its 2024 Annual Report and Sustainability Statement, showcasing significant progress in its three-year transformation journey. The company achieved 4% organic revenue growth and 18% operating income growth on an outlook base in 2024.
Key sustainability achievements include maintaining a high global patient Net Promoter Score of 72, conducting 22 clinical studies, and publishing 165 scientific research documents. The company operates 3,675 dialysis clinics serving approximately 299,000 patients worldwide.
Environmental initiatives resulted in a 25% reduction in Scope 1 and 2 emissions compared to 2020, with over 100 energy efficiency opportunities identified at production sites. The company also strengthened its financial foundation by reducing debt and increasing dividends, positioning itself for enhanced earnings growth in 2025.
Fresenius Medical Care (FMS) ha pubblicato il suo Rapporto Annuale e Dichiarazione di Sostenibilità per il 2024, evidenziando progressi significativi nel suo percorso di trasformazione triennale. L'azienda ha raggiunto una crescita organica dei ricavi del 4% e una crescita del reddito operativo del 18% rispetto alle previsioni per il 2024.
I principali risultati in materia di sostenibilità includono il mantenimento di un elevato punteggio globale di Net Promoter Score per i pazienti di 72, la conduzione di 22 studi clinici e la pubblicazione di 165 documenti di ricerca scientifica. L'azienda gestisce 3.675 cliniche per dialisi che servono circa 299.000 pazienti in tutto il mondo.
Le iniziative ambientali hanno portato a una riduzione del 25% delle emissioni di Scope 1 e 2 rispetto al 2020, con oltre 100 opportunità di efficienza energetica identificate nei siti di produzione. L'azienda ha anche rafforzato la sua base finanziaria riducendo il debito e aumentando i dividendi, posizionandosi per una crescita dei guadagni migliorata nel 2025.
Fresenius Medical Care (FMS) ha publicado su Informe Anual y Declaración de Sostenibilidad para 2024, mostrando avances significativos en su viaje de transformación de tres años. La empresa logró un crecimiento orgánico de ingresos del 4% y un crecimiento del ingreso operativo del 18% en base a las proyecciones para 2024.
Los logros clave en sostenibilidad incluyen el mantenimiento de un alto puntaje global de Net Promoter Score para pacientes de 72, la realización de 22 estudios clínicos y la publicación de 165 documentos de investigación científica. La empresa opera 3,675 clínicas de diálisis que atienden aproximadamente a 299,000 pacientes en todo el mundo.
Las iniciativas ambientales resultaron en una reducción del 25% en las emisiones de Alcance 1 y 2 en comparación con 2020, con más de 100 oportunidades de eficiencia energética identificadas en los sitios de producción. La empresa también fortaleció su base financiera al reducir la deuda y aumentar los dividendos, posicionándose para un crecimiento de ganancias mejorado en 2025.
프레제니우스 메디컬 케어 (FMS)는 2024년 연례 보고서 및 지속 가능성 보고서를 발표하며 3년간의 변혁 여정에서의 중요한 진전을 보여주었습니다. 이 회사는 2024년 전망 기준으로 4%의 유기적 수익 성장과 18%의 운영 소득 성장을 달성했습니다.
주요 지속 가능성 성과로는 전 세계 환자 순 추천 지수(Net Promoter Score)를 72로 유지하고, 22개의 임상 연구를 수행하며, 165개의 과학 연구 문서를 발표한 것이 포함됩니다. 이 회사는 전 세계 약 299,000명의 환자에게 서비스를 제공하는 3,675개의 투석 클리닉을 운영하고 있습니다.
환경 이니셔티브는 2020년 대비 범위 1 및 2 배출량을 25% 줄이는 결과를 가져왔으며, 생산 현장에서 100개 이상의 에너지 효율성 기회가 확인되었습니다. 또한, 이 회사는 부채를 줄이고 배당금을 늘려 재무 기반을 강화하여 2025년에는 더 나은 수익 성장에 대비하고 있습니다.
Fresenius Medical Care (FMS) a publié son Rapport Annuel et sa Déclaration de Durabilité pour 2024, mettant en avant des progrès significatifs dans son parcours de transformation de trois ans. L'entreprise a réalisé une croissance organique du chiffre d'affaires de 4% et une croissance du résultat opérationnel de 18% sur une base prévisionnelle pour 2024.
Parmi les principales réalisations en matière de durabilité, on peut citer le maintien d'un score Net Promoter Score pour les patients de 72, la réalisation de 22 études cliniques et la publication de 165 documents de recherche scientifique. L'entreprise gère 3 675 cliniques de dialyse qui servent environ 299 000 patients dans le monde entier.
Les initiatives environnementales ont entraîné une réduction de 25 % des émissions de Scope 1 et 2 par rapport à 2020, avec plus de 100 opportunités d'efficacité énergétique identifiées sur les sites de production. L'entreprise a également renforcé sa base financière en réduisant sa dette et en augmentant ses dividendes, se positionnant ainsi pour une croissance des bénéfices améliorée en 2025.
Fresenius Medical Care (FMS) hat seinen Jahresbericht und Nachhaltigkeitsbericht 2024 veröffentlicht und erhebliche Fortschritte auf seinem dreijährigen Transformationsweg aufgezeigt. Das Unternehmen erzielte ein organisches Umsatzwachstum von 4% und ein Betriebsergebniswachstum von 18% auf Basis der Prognosen für 2024.
Zu den wichtigsten Nachhaltigkeitsleistungen gehören die Aufrechterhaltung eines hohen globalen Net Promoter Scores von 72, die Durchführung von 22 klinischen Studien und die Veröffentlichung von 165 wissenschaftlichen Forschungsdokumenten. Das Unternehmen betreibt 3.675 Dialysekliniken, die weltweit etwa 299.000 Patienten versorgen.
Umweltinitiativen führten zu einer Reduzierung der Scope 1 und 2 Emissionen um 25% im Vergleich zu 2020, wobei an den Produktionsstandorten über 100 Möglichkeiten zur Energieeffizienz identifiziert wurden. Das Unternehmen hat auch seine finanzielle Basis gestärkt, indem es Schulden abgebaut und Dividenden erhöht hat, um sich für ein verbessertes Gewinnwachstum im Jahr 2025 zu positionieren.
- None.
- None.
- In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders
- Fresenius Medical Care delivered
18% operating income growth on an outlook base in 2024 - Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprint
BAD HOMBURG,
Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said: "The year 2024 marked the second year of a three-year transformation and turnaround journey for Fresenius Medical Care. With the major structural and legal changes undertaken in 2023, in 2024 our focus was on building momentum. Our efforts have been designed to strengthen our financial foundation – both for today and for future sustainable, profitable growth."
The 2024 Annual Report summarizes Fresenius Medical Care's steps to successfully deliver on the transformation. FME achieved important top- and bottom-line contributions, with
The report includes the company's Sustainability Statement, which provides a comprehensive overview of strategic priorities set to support the company's long-term sustainable development and continues to report on progress in its three focus areas:
Enhancing quality care and access to health care: In 2024, Fresenius Medical Care once again achieved a high global patient Net Promoter Score (NPS) of 72 (2023:72), which confirms the effectiveness of the company's patient experience measures. FME measures patient satisfaction in its dialysis clinics globally using the Net Promoter Score. With 22 ongoing clinical studies and 165 published scientific research documents, FME advanced scientific knowledge and contributed valuable insights to improving health care.
Building the best team to serve patients: In a year of transformation, Fresenius Medical Care conducted its 5th Global Employee Engagement Survey with a score of
Reducing the company's environmental footprint: In 2024, Fresenius Medical Care´s reported Scope 1 and Scope 2 emissions footprint declined by
The Annual Report is available for download here as pdf-file on the company's website.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-publishes-its-joint-annual-report-and-sustainability-statement-for-2024-building-the-momentum-302400896.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What were Fresenius Medical Care's (FMS) key financial achievements in 2024?
How many dialysis clinics does FMS operate globally as of 2024?
What environmental progress did FMS report in their 2024 sustainability statement?
How did FMS measure patient satisfaction in 2024?
What research and development activities did FMS conduct in 2024?
